^
    11ms
    The relationship between the risk factors of lung cancer and the prognosis and its mechanisms among Chinese patients (ChiCTR2400091378)
    P=N/A, N=1428, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    over1year
    Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam. (PubMed, Ther Adv Med Oncol)
    Afatinib is effective for locally advanced metastatic NSCLC with uncommon EGFR mutations. Patients with G719X, compound G719X-S768I mutations, and tolerated doses of 20 or 30 mg had a longer median TTF than those with other mutations.
    Clinical • Journal • Real-world evidence • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    |
    Gilotrif (afatinib)
    2years
    Exploring the conformational dynamics and thermodynamics of EGFR S768I and G719X + S768I mutations in non-small cell lung cancer: An in silico approaches. (PubMed, Open Life Sci)
    The present study may be helpful in the development of new EGFR-targeted drugs based on the structure of rare mutations. Our findings may aid in developing new targeted treatments for patients with EGFR S768I and EGFR G719X + S768I mutations.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR wild-type • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I • EGFR G719C
    over2years
    Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience (ESMO 2023)
    Dacomitinib is active in pts with brain metastasis, uncommon EGFR mutation, in patients with poor PS, and at 30 mg starting dose. Dacomitinib showed very good PFS with manageable safety profile.
    Clinical • Real-world evidence • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    |
    Vizimpro (dacomitinib)
    over2years
    Real World Analysis Afatinib as a First Line Treatment Patients with Advanced Stage Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations (IASLC-WCLC 2023)
    Afatinib was an effective treatment option in patients with locally advanced and metastatic NSCLC harboring uncommon EGFR mutations. Patients with the EGFR mutations at G719X, compound G719X-S768I and tolerated dose of 20 mg or 30 mg tended to achieve a longer median TTF than those with others.
    Clinical • Real-world evidence • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    |
    Gilotrif (afatinib)
    over2years
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2b, N=99, Recruiting, Teligene US | Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Aug 2024
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    |
    sutetinib (SZMD4)
    over3years
    High Frequency of KRAS Mutation, Uncommon EGFR Mutation and TMB-H in Xuanwei Female Patients With Lung Adenocarcinoma (IASLC-WCLC 2022)
    In conclusion, the present study evidenced that Xuanwei female patients with LUAC had specific genetic profile when compared to reference Chinese female patients, indicating this high-risk female population could possibly benefit from therapy targeting KRAS mutation, uncommon EGFR mutations and HRR pathway deficiency, as well as immunotherapy.
    Clinical • Tumor Mutational Burden • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • LRP1B (LDL Receptor Related Protein 1B) • RBM10 (RNA Binding Motif Protein 10)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • TMB-H • KRAS G12C • EGFR L858R • EGFR exon 19 deletion • KRAS G12V • EGFR L861Q • EGFR G719X • EGFR S768I • KRAS G12 • EGFR G719X + EGFR S768I
    over3years
    Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China. (PubMed, Genes Environ)
    This findings of this study might be important in establishing the correlation between routine using NGS for EGFR gene mutation diagnosis and clinical practice in the lung cancer patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    over3years
    Mefatinib as first-line treatment of patients with advanced non–small cell lung cancer harboring rare EGFR mutations. (ASCO 2022)
    Mefatinib has shown promising anti-tumor activity and a favorable safety profile in patients with advanced NSCLC harboring rare EGFR mutations.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    |
    mefatinib (MET306)
    over3years
    Genomic characteristics of classic and uncommon EGFR activating mutations explains different responses to first-generation EGFR-TKIs (AACR 2022)
    This comprehensive analysis of EGFR-positive mutational landscape revealed specific genomic characteristics associated with uncommon EGFR mutations that might explain their poor response to first-generation TKIs.
    Tumor Mutational Burden • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • GATA6 (GATA Binding Protein 6) • EPHA3 (EPH receptor A3)
    |
    TP53 mutation • EGFR mutation • TMB-H • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR positive • EGFR G719X + EGFR S768I
    almost4years
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2b, N=99, Not yet recruiting, Teligene US
    Clinical • New P2b trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    5years
    Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases. (PubMed, Clin Lung Cancer)
    No intra- or intertumor heterogeneity was observed for EGFR compound mutations. Our results indicate that both EGFR mutations were truncal and selective elimination of cancer cells with uncommon EGFR mutations is unrealistic.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR L858R • EGFR G719X • EGFR S768I • EGFR G719A • EGFR G719X + EGFR S768I • EGFR E709G • EGFR G719A + EGFR S768I • EGFR L858R + EGFR R776H • EGFR L858R + EGFR S768I